Sensei Biotherapeutics (SNSE) Stock: Buy, Sell, or Hold?
SNSE - Sensei Biotherapeutics, Inc. Common Stock
$13.85
0.85 (6.54%)
â˛
5d:
+6.54%
30d:
-30.12%
90d:
-53.68%
WAIT
LOW Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When SNSE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SNSE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SNSE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SNSE is currently trading at $13.85, which is considered fair based on recent price action.
Technical Outlook: Technically, SNSE is in a uptrend. Immediate support is located at $12.35, while resistance sits at $21.50. The stock is showing strong short-term momentum, up 6.5% recently.
Market Sentiment: SNSE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.50 (+279.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNSE is in a uptrend. Immediate support is located at $12.35, while resistance sits at $21.50. The stock is showing strong short-term momentum, up 6.5% recently.
Market Sentiment: SNSE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.50 (+279.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
53/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: Strong upward momentum (+6.5%)
- BULLISH: Trading 279.1% below Wall St target ($52.50)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$12.35
Resistance Level
$21.50
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.75
Wall Street Target
$52.50
(+279.1%)
Share & Embed Analysis
Last updated: September 13, 2026 11:18 AM ET
Data refreshes hourly during market hours. Next update: 12:18 PM
Data refreshes hourly during market hours. Next update: 12:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNSE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
BUY
20 analysts |
$34 | 52 HOLD |
